Review: Mechanotransduction in Ovarian Cancer: Shearing into the Unknown

Overview

Journal APL Bioeng

Date 2019 May 10

PMID 31069311

Citations 39

Authors

Caymen Novak

Eric Horst

Geeta Mehta

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment.

Citing Articles

Cisplatin resistance alters ovarian cancer spheroid formation and impacts peritoneal invasion.

Powell L, Quintela M, James D, Onyido E, Howard D, Edwards K Front Cell Dev Biol. 2025; 13:1450407.

PMID: 39974724 PMC: 11836028. DOI: 10.3389/fcell.2025.1450407.

Ascitic Shear Stress Activates GPCRs and Downregulates Mucin 15 to Promote OvarianCancer Malignancy.

Mehta G, Horst E, Cotter L, Bonini M, Novak C, Treacher N Res Sq. 2024; .

PMID: 39483899 PMC: 11527234. DOI: 10.21203/rs.3.rs-5160301/v1.

Probing T-cell activation in nanoliter tumor co-cultures using membrane displacement trap arrays.

Yeh M, Salazar-Cavazos E, Krishnan A, Altan-Bonnet G, DeVoe D Integr Biol (Camb). 2024; 16.

PMID: 39074471 PMC: 11286267. DOI: 10.1093/intbio/zyae014.

STAT3 mediates ECM stiffness-dependent progression in ovarian cancer.

Chenchen S, Xueqian Q, Yahui L, Yi Y, Hui Z, Lanning B Mol Cell Biochem. 2024; 480(1):607-620.

PMID: 38625514 DOI: 10.1007/s11010-024-04991-5.

Cancer cell response to extrinsic and intrinsic mechanical cue: opportunities for tumor apoptosis strategies.

Shu J, Deng H, Zhang Y, Wu F, He J Regen Biomater. 2024; 11:rbae016.

PMID: 38476678 PMC: 10932484. DOI: 10.1093/rb/rbae016.

References

Mo L, Bachelder R, Kennedy M, Chen P, Chi J, Berchuck A . Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. Mol Cancer Ther. 2015; 14(3):747-56. PMC: 4765908. DOI: 10.1158/1535-7163.MCT-14-0579. View

Loessner D, Stok K, Lutolf M, Hutmacher D, Clements J, Rizzi S . Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010; 31(32):8494-506. DOI: 10.1016/j.biomaterials.2010.07.064. View

Szotek P, Pieretti-Vanmarcke R, Masiakos P, Dinulescu D, Connolly D, Foster R . Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006; 103(30):11154-9. PMC: 1544057. DOI: 10.1073/pnas.0603672103. View

Egan K, Cooke N, Kenny D . Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis. 2014; 31(6):697-704. DOI: 10.1007/s10585-014-9660-7. View

Mitchell M, King M . Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013; 3:44. PMC: 3587800. DOI: 10.3389/fonc.2013.00044. View

Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod S . Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016; 143(2):433-438. DOI: 10.1016/j.ygyno.2016.08.320. View

Dijk M, Goransson S, Stromblad S . Cell to extracellular matrix interactions and their reciprocal nature in cancer. Exp Cell Res. 2013; 319(11):1663-70. DOI: 10.1016/j.yexcr.2013.02.006. View

Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y . Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003; 9(7):2632-41. View

Cvetkovic D . Early events in ovarian oncogenesis. Reprod Biol Endocrinol. 2003; 1:68. PMC: 239895. DOI: 10.1186/1477-7827-1-68. View

10.

Lesman A, Blinder Y, Levenberg S . Modeling of flow-induced shear stress applied on 3D cellular scaffolds: Implications for vascular tissue engineering. Biotechnol Bioeng. 2009; 105(3):645-54. DOI: 10.1002/bit.22555. View

11.

Carduner L, Leroy-Dudal J, Picot C, Gallet O, Carreiras F, Kellouche S . Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins. Clin Exp Metastasis. 2014; 31(6):675-88. DOI: 10.1007/s10585-014-9658-1. View

12.

Curley M, Garrett L, Schorge J, Foster R, Rueda B . Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci (Landmark Ed). 2011; 16(1):368-92. DOI: 10.2741/3693. View

13.

Rizzo S, Hersey J, Mellor P, Dai W, Santos-Silva A, Liber D . Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011; 10(2):325-35. PMC: 3037846. DOI: 10.1158/1535-7163.MCT-10-0788. View

14.

Yousif N . Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int. 2013; 38(1):85-91. DOI: 10.1002/cbin.10184. View

15.

Ahmed N, Abubaker K, Findlay J, Quinn M . Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010; 10(3):268-78. DOI: 10.2174/156800910791190175. View

16.

Yoon A, Stasinopoulos I, Kim J, Yong H, Kilic O, Wirtz D . COX-2 dependent regulation of mechanotransduction in human breast cancer cells. Cancer Biol Ther. 2015; 16(3):430-7. PMC: 4622920. DOI: 10.1080/15384047.2014.1003004. View

17.

Auersperg N, Ota T, Mitchell G . Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer. 2002; 12(6):691-703. DOI: 10.1046/j.1525-1438.2002.01152.x. View

18.

FELDMAN G, Knapp R, ORDER S, Hellman S . The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 1972; 32(8):1663-6. View

19.

Schrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S . Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011; 53(4):1192-205. PMC: 3076070. DOI: 10.1002/hep.24108. View

20.

Li B, Zhao W, Tan Z, Fang W, Zhu L, Chen Y . Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett. 2006; 580(17):4252-60. DOI: 10.1016/j.febslet.2006.06.056. View